Kafin mu fara, ina so in jaddada cewa, ga waɗanda ke sha'awar dukan labarin yadda ake kula da cutar mata , za a karanta wannan labarin game da alamar testosterone a cikin wasu abubuwa biyu da na rubuta: Viagra ga mata da new-yet unapproved - mace jima'i kwaya flibanserin . Mafi mahimmanci, gurbin testosterone yana wakiltar matsakaicin matsakaici na wannan jima'i na jima'i: wata hanya ta gwadawa bayan Pfizer ya daina tsayar da hanyar Viagra ga mata da kuma gaban ci gaban flibanserin, wata jima'i na miyagun ƙwayoyi da ke jaddada matakan neurotransmitter.
Nazarin kan Maganin Jima'i na Mata
Matsayin da dukkanin yunkuri na jiyya ga aikin mata na jima'i yana komawa zuwa labarin 1999 wanda aka wallafa a JAMA wanda ake kira "binciken na 43-31". Masu bincike daga wannan binciken sun nuna cewa fiye da 4 daga cikin 10 mata (kashi 43) suna da matsalolin jima'i idan aka kwatanta da kashi 31 cikin dari na maza. Wannan binciken ya shimfiɗa abin da ya ci gaba da kasancewa rubutun a kowace muhawara game da maganin rashin jima'i na mata; wanda ya zama kamfanonin kamfanonin kamfanoni da kuma masu sana'a da yawa a gefe ɗaya, kuma masu sukar suna cewa cewa lalata yanayin jima'i kamar yadda wani misali ne na "mongering" a gefe ɗaya.
A ranar 21 ga watan Yuni, 2004, Proctor & Gamble ya bukaci FDA ta amince da sabon tsarin tsarin testosterone (transmitmal patch), Intrinsa. An yi intrinsa kamar:
Yin jiyya na rashin jin dadin jima'i a cikin mata masu mata masu mata suna samun maganin isrogen. Halin da ake ciki na halayen jima'i (HSDD) shine jiguwa ko raguwar lokaci ko rashin jima'i, jima'i, da kuma sha'awar yin jima'i, wanda zai haifar da matsanancin matsala ko matsalolin dangi. Ƙananan sha'awar jima'i na iya kasancewa tare da rashin yin jima'i, matsalolin jima'i ko matsalolin haɗari.
Kamar yadda aka gani a cikin halin da nake ciki na rashin cin zarafi na mata , HSDD wani lokaci ne wanda ba a san shi ba. A zamanin yau, DSM-5 yayi magana game da "jima'i da jima'i na mata" wanda ya haɗu da matsalolin sha'awar sha'awar zuciya a cikin ɗayan ɗayan ɗakin.
Sakamakon binciken gwaji na P & G na 3 na gwajin gwagwarmaya ya nuna cewa a cikin mata da 2 zuwa 3 abubuwan da suka faru na jima'i a kowanne wata, gwamnati ta 300 μg (amma ba 150 μg ko 450 μg) an danganta da wani ƙarin abubuwan jima'i a cikin wata guda.
Don dalilai 2 masu dalili, FDA ta ƙi yarda da Intrinsa. Na farko, wadannan sakamakon ba su da ma'ana. A cikin mutanen da suke da jima'i na yau da kullum da kuma jima'i , wani karamin testosterone yana ƙaruwa yawan abubuwan da suka faru da jima'i ta hanyar daya a wata! Abu na biyu, saboda wannan kawai wani karin jima'i na jima'i, matan da ke da ma'aurata da suka yi amfani da estrogen za su kasance sun nunawa ga wani hormone mai hatsarin gaske, testosterone. Bari in bayyana.
Yayin da P & G ke neman amincewa da takaddun shaidar testosterone, kowa yana ketawa sakamakon sakamakon da ya ke fitowa daga binciken Nazarin Lafiya na Mata na nazarin kariyar hormone. A wannan lokacin, sakamakon binciken da aka gabatar daga wannan binciken ya nuna cewa tsarin yaduwar isrogen da kuma yaduwar cutar ga mata bayan da aka yi amfani da kwayar cutar ta kara yawan hadarin cerebrovascular (tunanin fashewar), ciwon zuciya da jijiyar nono. FDA ta kammala cewa ba tare da nazarin lokaci na tsawo ba, yana da ha ari ga ba da mata testosterone da sauran kwayoyin hormones. Daga bayanin kula, nazarin binciken na P & G ya kimanta yawancin testosterone a cikin mahalarta na mako 52 a mafi yawancin.
Dangane da farfadowar FDA, P & G ya ga rashin amfani na turawa batun kuma ya bar Intrinsa.
A cikin tsinkaya, a bayyane yake cewa P & G yana fatan cewa likitoci za su rubuta takardun testosterone don kashewa-amfani da lakabin-musamman, a cikin mata banda waɗanda suka samu tursasawa a lokacin tiyata. Saboda rashin bincike na dogon lokaci, FDA ya nuna damuwa da wannan yiwuwar.
Akwai wasu binciken binciken da suka yi tambaya game da tasirin testosterone mai inganci a matsayin mai shiga tsakani ga mutanen da ke tattare da jima'i. Na farko, ba mu da shaida na aikin low-androgen a cikin mata da dysfunction jima'i. Abu na biyu, kodayake zamu iya auna ƙwayar intracrine ko kwayoyin testosterone, ba za mu iya auna matakan testosterone a cikin tsarin kulawa na tsakiya ba.
Matakan Testosterone a cikin tsarin kulawa na tsakiya sunyi tasiri sosai akan sha'awar da sha'awar.
Shin mata suna bukatar karin Testosterone?
A wasu kalmomi, ba mu da wata masani ko matakan testosterone a cikin kwakwalwa da kuma kashin baya na waɗanda ke fama da jima'i ba su da kasa don buƙatar ƙarin ƙarin testosterone, don farawa. Abu na uku, ko da a cikin kwayoyin testosterone da alamun da aka yi wa maza, ba mu san yadda yawancin testosterone za suyi amfani da su ba don haka suyi amfani da su sosai a cikin kwayoyin testosterone.
Amma a nan ne abu. Ga mata da yawa, samun dama ga testosterone a wasu nau'i ne mai yiwuwa. Alal misali, mata da mata masu sha'awar jima'i / damuwa har yanzu ana iya sanya takardu da kwayoyin testosterone da alamomi (shan magani na maza). Karin bayani na Testosterone kuma sun zo a cikin tsarin halitta wanda za'a iya saya akan Intanit. A} arshe, a wasu} asashe, ana ba da wata kalma ga mata da halayyar mata.
Saboda haka, a cikin duka, har yanzu akwai hanyoyi don samun hannayenku ga testosterone don bi da lalata mata ; Duk da haka, ba abin da muka sani ba, yana yiwuwa mai kyau ra'ayin da za a kawar da kayan. Bincike ya nuna babu wani amfani na asibiti wanda yafi dacewa da ƙwayar testosterone a cikin mata da mata masu cin zarafin mata, kuma ba ma san ko matakan testosterone ba su raguwa a cikin mata masu fama da jima'i a farko. Kuma, ba shakka, testosterone wani hormone ne, kuma an san cewa suna da mummunar illa kamar cututtuka, yatsun jini, ciwon daji da sauransu.
> Sources:
> Mataki na ashirin da "mai suna" Testosterone farfesa don rage libido a cikin mata "da R Basson ya buga a Ci gaban Turawa a Endocrinology da Metabolism da aka buga a 2010. An samu damar ranar 3/13/2015.
> Mataki na ashirin da daya da ake kira "Cibiyar Al'adu Viagra: Damag Industry Essential to Create and Repackage Sex Drugs for Women" by Heather Hartley da aka buga a cikin jima'i a shekara ta 2006. An sami damar shiga ranar 3/15/2015.